Senolytic Combination of Dasatinib and Quercetin: a Review of Preclinical and Clinical Studies
Year: 2025
Type: article
Abstract: Societal modernization is driving a steady rise in life expectancy alongside declining birth rates. This demographic transition places a significant burden on social institutions, particularly healthcare systems. Age-related diseases are the leading cause of mortality globally: over 80% of individuals over 65 live with at least one chronic condition, and half of this group suffers from multiple comorbidities. Developing therapeutics that target the fundamental mechanisms of aging is a promising strategy for improving treatment outcomes for age-related diseases and, ultimately, enhancing the quality of life in the elderly. This review aims to present findings from preclinical and clinical studies on the combination of dasatinib and quercetin. It is based on an analysis of literature, primarily international but also including domestic sources, indexed in PubMed and eLibrary databases and retrieved via Google Scholar over the past decade. Analysis of available data suggests that selectively clearing senescent cells (senolysis) is a promising therapeutic strategy for preventing and treating many chronic age-related diseases. However, further research is necessary to confirm the clinical potential of this drug combination, specifically its safety profile, pharmacokinetics, and pharmacodynamics. Additionally, there is an urgent need to identify relevant and reliable biomarkers to objectively assess the efficacy of senolytic therapies. Keywords: celluar senescence; senolytics; dasatinib; quercetin; SASP.
Authors: I.I. Morozov, N.N. Molkanov, N.M. Kiseleva
Institution: Pirogov Russian National Research Medical University
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7141240174
